ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Conditions

Subcategories:Axial SpondyloarthritisClinical Criteria/GuidelinesGout and Crystalline ArthritisMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis

The History & Future of Anti-Citrullinated Protein Antibodies (ACPAs)

Ruth Jessen Hickman, MD  |  March 18, 2019

Anti-citrullinated protein antibodies (ACPAs) are now viewed as critical diagnostic and prognostic markers for rheumatoid arthritis (RA). Research into the pathophysiology of these autoantibodies has proven to be a ripe area of investigation, opening up many promising avenues for better understanding the etiology and pathogenesis of RA. Ultimately, work utilizing these autoantibodies may also allow…

Lightspring / shutterstock.com

Recent Research Probes Smoking & the Risk for Autoimmune Disease

Vanessa Caceres  |  March 18, 2019

It’s no secret to any health professional, including rheumatologists, that smoking cigarettes or using other tobacco-based products is unhealthy. Yet how does smoking specifically affect rheumatic diseases, and what are some of the newest findings in this area? What role do e-cigarettes have in the smoking risk landscape? Those are the sorts of questions asked…

Hip Exercises May Improve Walking, Pain with Knee Arthritis

Carolyn Crist  |  March 13, 2019

(Reuters Health)—Patients with knee osteoarthritis (OA) can add hip-strengthening exercises to their workout to improve the ability to walk and maybe reduce pain, according to a research review. Based on pooled data from eight clinical trials with a total of 340 patients, hip strengthening exercises involving weights or elastic bands would help the most, the…

FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare

Michele B. Kaufman, PharmD, BCGP  |  March 12, 2019

The FDA has issued a boxed warning for febuxostat after a safety study found an increased risk of heart-related and other death in RA patients…

Metabolic Profiling of SLE

Lara C. Pullen, PhD  |  March 12, 2019

Research examining the metabolic profile of SLE found increased oxidative activity, as well as lower levels of tyrosine and tryptophan, in SLE patients relative to controls, suggesting increased activity of aromatic amino acid decarboxylase. The results suggest metabolomics may have the ability to measure disease severity in SLE…

Coding Corner Question: Use Level 3 or 4 for RA/Gout Patient?

From the College  |  March 11, 2019

A 60-year-old man returns for a follow-up related to his diagnoses of rheumatoid arthritis and chronic gout of his right ankle and foot, without tophi. He reports the gout flares have subsided in his ankle. He takes 450 mg of allopurinol daily. He has rheumatoid factor-positive rheumatoid arthritis, which previously affected multiple sites, without organ…

Coding Corner Answer: Use Level 3 or 4 for RA/Gout Patient?

From the College  |  March 11, 2019

Take the challenge. CPT: 20611-LT, J7325-EJ ICD-10: M17.12, E66.01, Z68.41 CPT: 99213 ICD-10: M1a.0710, M05.79 History—The history of present illness was extended. The review of systems was extended, and two past family social history elements were documented. This makes the history level detailed. Examination—Five systems were examined. This makes the exam level detailed. Medical decision…

Rheumatoid Arthritis Risk Lower Among Smokers Who Quit

Lisa Rapaport  |  March 5, 2019

(Reuters Health)—Adults who quit smoking decades ago may have a lower risk of rheumatoid arthritis (RA) than people who gave up cigarettes more recently, a U.S. study suggests. Smoking has long been linked to an increased risk of RA, and quitting can reduce this risk. But the new study offers fresh evidence that years of…

GI Disease in Early Systemic Sclerosis Associated with Worse Outcomes

Lara C. Pullen, PhD  |  March 5, 2019

In patients with systemic sclerosis (SSc), gastrointestinal disease may be associated with lower quality of life and increased risk of death. Research showed that SSc patients with severe GI disease had markers of muscle inflammation, skin fibrosis and vasculopathy…

Duration & Treatment of Musculoskeletal Symptoms of Immunotherapy-Induced Arthritis

Arthritis Care & Research  |  March 4, 2019

A new case series outlines the treatment and duration of symptoms of 10 patients experiencing the musculoskeletal manifestations of immune-related adverse events. Researchers found these symptoms may last for more than a year, but can generally be treated with low to moderate doses of corticosteroids…

  • « Previous Page
  • 1
  • …
  • 133
  • 134
  • 135
  • 136
  • 137
  • …
  • 345
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences